The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Angioplasty

  • We compared the efficacy of immediate coronary angioplasty after acute myocardial infarction with that of elective angioplasty at 7 to 10 days in patients treated initially with intravenous tissue plasminogen activator [1].
  • Bivalirudin was at least as effective as high-dose heparin in preventing ischemic complications in patients who underwent angioplasty for unstable angina, and it carried a lower risk of bleeding [2].
  • Improved cardiac functional status after sustained successful coronary angioplasty was demonstrated by an almost normal capacity on bicycle exercise testing and the absence of ischemia during thallium isotope studies in 80 per cent [3].
  • End-point data were available for 56 patients randomly assigned to receive tissue plasminogen activator (mean [+/- SD] time to start of infusion, 232 +/- 174 minutes after the onset of chest pain) and 47 patients randomly assigned to receive angioplasty (first balloon inflation at 277 +/- 144 minutes) [4].
  • We used the search terms heart failure, congestive; congestive heart failure; heart failure; cardiac failure; and dilated cardiomyopathy in conjunction with the terms coronary artery bypass grafting and angioplasty [5].

Psychiatry related information on Angioplasty


High impact information on Angioplasty

  • We designed this study to evaluate the effect of lowering plasma homocysteine levels on restenosis after coronary angioplasty [9].
  • CONCLUSIONS: Treatment with a combination of folic acid, vitamin B12, and pyridoxine significantly reduces homocysteine levels and decreases the rate of restenosis and the need for revascularization of the target lesion after coronary angioplasty [9].
  • As compared with the patients who were treated with angioplasty and usual care, the patients who received atorvastatin had a significantly longer time to the first ischemic event (P=0.03) [10].
  • This difference resulted from a smaller mean (+/-SD) minimal luminal diameter in the angioplasty group (1.85+/-0.56 mm) than in the stent group (2.04+/-0.66 mm), with a mean difference of 0.19 mm (P=0.01) at follow-up [11].
  • Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty [12].

Chemical compound and disease context of Angioplasty


Biological context of Angioplasty


Anatomical context of Angioplasty


Associations of Angioplasty with chemical compounds

  • Of the 15 myocardial regions with defects on redistribution studies that were identified as viable by reinjection studies before angioplasty, 13 (87 percent) had normal thallium uptake and improved regional wall motion after angioplasty [28].
  • These patients had total cholesterol levels ranging from 160 to 300 mg per deciliter (4.1 to 7.8 mmol per liter) and were undergoing coronary angioplasty [29].
  • Probucol and multivitamins in the prevention of restenosis after coronary angioplasty [30].
  • Local effect of serotonin released during coronary angioplasty [18].
  • Coronary bypass surgery was needed in 7.5 percent of the patients in the pravastatin group and 10 percent of those in the placebo group, a 26 percent reduction (P=0.005), and coronary angioplasty was needed in 8.3 percent of the pravastatin group and 10.5 percent of the placebo group, a 23 percent reduction (P=0.01) [31].

Gene context of Angioplasty

  • More importantly, the observation that PDE1C is induced only in proliferating SMCs suggests that it may be both an indicator of proliferation and a possible target for treatment of atherosclerosis or restenosis after angioplasty, conditions in which proliferation of arterial SMCs is negatively modulated by cyclic nucleotides [32].
  • A parallel but marked increase in ETA and ETB receptor mRNAs compared with preproET-1 and -3 messages was observed after angioplasty [33].
  • The increase in ETB receptor mRNA occurred slightly earlier than the increase in ETA receptor mRNA, showing 15.1-fold increase at 1 day (P < .001) and 11.3-fold increase at 3 days (P < .01) after angioplasty [33].
  • A similarly delayed increase in preproET-3 mRNA was observed at 7 days (2.8-fold increase, P < .05) and 14 days (2.6-fold increase, P < .05) after angioplasty [33].
  • Thus, VSMC proliferation after angioplasty in the rat carotid artery is associated with a temporally and spatially coordinated expression of cdk2, cyclins E and A, and PCNA [34].

Analytical, diagnostic and therapeutic context of Angioplasty


  1. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. Topol, E.J., Califf, R.M., George, B.S., Kereiakes, D.J., Abbottsmith, C.W., Candela, R.J., Lee, K.L., Pitt, B., Stack, R.S., O'Neill, W.W. N. Engl. J. Med. (1987) [Pubmed]
  2. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. Bittl, J.A., Strony, J., Brinker, J.A., Ahmed, W.H., Meckel, C.R., Chaitman, B.R., Maraganore, J., Deutsch, E., Adelman, B. N. Engl. J. Med. (1995) [Pubmed]
  3. Emergency coronary angioplasty in refractory unstable angina. de Feyter, P.J., Serruys, P.W., van den Brand, M., Balakumaran, K., Mochtar, B., Soward, A.L., Arnold, A.E., Hugenholtz, P.G. N. Engl. J. Med. (1985) [Pubmed]
  4. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups. Gibbons, R.J., Holmes, D.R., Reeder, G.S., Bailey, K.R., Hopfenspirger, M.R., Gersh, B.J. N. Engl. J. Med. (1993) [Pubmed]
  5. Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. Baker, D.W., Jones, R., Hodges, J., Massie, B.M., Konstam, M.A., Rose, E.A. JAMA (1994) [Pubmed]
  6. Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. O'Connor, G.T., Quinton, H.B., Traven, N.D., Ramunno, L.D., Dodds, T.A., Marciniak, T.A., Wennberg, J.E. JAMA (1999) [Pubmed]
  7. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. Ferguson, J.J., Dougherty, K.G., Gaos, C.M., Bush, H.S., Marsh, K.C., Leachman, D.R. J. Am. Coll. Cardiol. (1994) [Pubmed]
  8. Influence of alcohol consumption on restenosis rate after percutaneous transluminal coronary angioplasty and stent implantation. Niroomand, F., Hauer, O., Tiefenbacher, C.P., Katus, H.A., Kuebler, W. Heart (2004) [Pubmed]
  9. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. Schnyder, G., Roffi, M., Pin, R., Flammer, Y., Lange, H., Eberli, F.R., Meier, B., Turi, Z.G., Hess, O.M. N. Engl. J. Med. (2001) [Pubmed]
  10. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. Pitt, B., Waters, D., Brown, W.V., van Boven, A.J., Schwartz, L., Title, L.M., Eisenberg, D., Shurzinske, L., McCormick, L.S. N. Engl. J. Med. (1999) [Pubmed]
  11. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. Erbel, R., Haude, M., Höpp, H.W., Franzen, D., Rupprecht, H.J., Heublein, B., Fischer, K., de Jaegere, P., Serruys, P., Rutsch, W., Probst, P. N. Engl. J. Med. (1998) [Pubmed]
  12. Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty. Gambassi, G., Landolfi, R., Bernabei, R. N. Engl. J. Med. (1997) [Pubmed]
  13. Pharmacologic stress imaging. Beller, G.A. JAMA (1991) [Pubmed]
  14. Transient release of lipid peroxides after coronary artery balloon angioplasty. Roberts, M.J., Young, I.S., Trouton, T.G., Trimble, E.R., Khan, M.M., Webb, S.W., Wilson, C.M., Patterson, G.C., Adgey, A.A. Lancet (1990) [Pubmed]
  15. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. Cannon, C.P., McCabe, C.H., Borzak, S., Henry, T.D., Tischler, M.D., Mueller, H.S., Feldman, R., Palmeri, S.T., Ault, K., Hamilton, S.A., Rothman, J.M., Novotny, W.F., Braunwald, E. Circulation (1998) [Pubmed]
  16. Dobutamine echocardiography in myocardial hibernation. Optimal dose and accuracy in predicting recovery of ventricular function after coronary angioplasty. Afridi, I., Kleiman, N.S., Raizner, A.E., Zoghbi, W.A. Circulation (1995) [Pubmed]
  17. Inhibition of platelet-dependent thrombosis by local delivery of heparin with a hydrogel-coated balloon. Nunes, G.L., Thomas, C.N., Hanson, S.R., Barry, J.J., King, S.B., Scott, N.A. Circulation (1995) [Pubmed]
  18. Local effect of serotonin released during coronary angioplasty. Golino, P., Piscione, F., Benedict, C.R., Anderson, H.V., Cappelli-Bigazzi, M., Indolfi, C., Condorelli, M., Chiariello, M., Willerson, J.T. N. Engl. J. Med. (1994) [Pubmed]
  19. Newer tests for the diagnosis of renovascular disease. Davidson, R.A., Wilcox, C.S. JAMA (1992) [Pubmed]
  20. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". Reverter, J.C., Béguin, S., Kessels, H., Kumar, R., Hemker, H.C., Coller, B.S. J. Clin. Invest. (1996) [Pubmed]
  21. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Isner, J.M., Pieczek, A., Schainfeld, R., Blair, R., Haley, L., Asahara, T., Rosenfield, K., Razvi, S., Walsh, K., Symes, J.F. Lancet (1996) [Pubmed]
  22. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Bonnefoy, E., Lapostolle, F., Leizorovicz, A., Steg, G., McFadden, E.P., Dubien, P.Y., Cattan, S., Boullenger, E., Machecourt, J., Lacroute, J.M., Cassagnes, J., Dissait, F., Touboul, P. Lancet (2002) [Pubmed]
  23. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Ferns, G.A., Raines, E.W., Sprugel, K.H., Motani, A.S., Reidy, M.A., Ross, R. Science (1991) [Pubmed]
  24. Femoral artery recanalisation with percutaneous angioplasty and segmentally enclosed plasminogen activator. Jørgensen, B., Tønnesen, K.H., Bülow, J., Nielsen, J.D., Jørgensen, M., Holstein, P., Andersen, E. Lancet (1989) [Pubmed]
  25. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Ohlstein, E.H., Douglas, S.A., Sung, C.P., Yue, T.L., Louden, C., Arleth, A., Poste, G., Ruffolo, R.R., Feuerstein, G.Z. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  26. How does angioplasty work? Serial analysis of human iliac arteries using intravascular ultrasound. Losordo, D.W., Rosenfield, K., Pieczek, A., Baker, K., Harding, M., Isner, J.M. Circulation (1992) [Pubmed]
  27. Predictors and sequelae of distal embolization during saphenous vein graft intervention from the CAVEAT-II trial. Coronary Angioplasty Versus Excisional Atherectomy Trial. Lefkovits, J., Holmes, D.R., Califf, R.M., Safian, R.D., Pieper, K., Keeler, G., Topol, E.J. Circulation (1995) [Pubmed]
  28. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. Dilsizian, V., Rocco, T.P., Freedman, N.M., Leon, M.B., Bonow, R.O. N. Engl. J. Med. (1990) [Pubmed]
  29. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. Treasure, C.B., Klein, J.L., Weintraub, W.S., Talley, J.D., Stillabower, M.E., Kosinski, A.S., Zhang, J., Boccuzzi, S.J., Cedarholm, J.C., Alexander, R.W. N. Engl. J. Med. (1995) [Pubmed]
  30. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Lisi, D.M. N. Engl. J. Med. (1997) [Pubmed]
  31. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G., Brown, L., Warnica, J.W., Arnold, J.M., Wun, C.C., Davis, B.R., Braunwald, E. N. Engl. J. Med. (1996) [Pubmed]
  32. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. Rybalkin, S.D., Bornfeldt, K.E., Sonnenburg, W.K., Rybalkina, I.G., Kwak, K.S., Hanson, K., Krebs, E.G., Beavo, J.A. J. Clin. Invest. (1997) [Pubmed]
  33. Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat. Wang, X., Douglas, S.A., Louden, C., Vickery-Clark, L.M., Feuerstein, G.Z., Ohlstein, E.H. Circ. Res. (1996) [Pubmed]
  34. Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Wei, G.L., Krasinski, K., Kearney, M., Isner, J.M., Walsh, K., Andrés, V. Circ. Res. (1997) [Pubmed]
  35. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Brener, S.J., Barr, L.A., Burchenal, J.E., Katz, S., George, B.S., Jones, A.A., Cohen, E.D., Gainey, P.C., White, H.J., Cheek, H.B., Moses, J.W., Moliterno, D.J., Effron, M.B., Topol, E.J. Circulation (1998) [Pubmed]
  36. One-year follow-up in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT I). Elliott, J.M., Berdan, L.G., Holmes, D.R., Isner, J.M., King, S.B., Keeler, G.P., Kearney, M., Califf, R.M., Topol, E.J. Circulation (1995) [Pubmed]
  37. Geometric remodeling is not the principal pathogenetic process in restenosis after balloon angioplasty. Evidence from correlative angiographic-histomorphometric studies of atherosclerotic arteries in rabbits. Gertz, S.D., Gimple, L.W., Banai, S., Ragosta, M., Powers, E.R., Roberts, W.C., Perez, L.S., Sarembock, I.J. Circulation (1994) [Pubmed]
  38. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]. Mark, D.B., Cowper, P.A., Berkowitz, S.D., Davidson-Ray, L., DeLong, E.R., Turpie, A.G., Califf, R.M., Weatherley, B., Cohen, M. Circulation (1998) [Pubmed]
  39. Increased formation of the isoprostanes IPF2alpha-I and 8-epi-prostaglandin F2alpha in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Reilly, M.P., Delanty, N., Roy, L., Rokach, J., Callaghan, P.O., Crean, P., Lawson, J.A., FitzGerald, G.A. Circulation (1997) [Pubmed]
WikiGenes - Universities